2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
157
Lung Neoplasms
73
Carcinoma, Hepatocellular
63
Small Cell Lung Carcinoma
52
Breast Neoplasms
47
Squamous Cell Carcinoma of Head and Neck
36
Urinary Bladder Neoplasms
30
Colorectal Neoplasms
30
Neoplasms
29
Biliary Tract Neoplasms
29
Neoplasm Metastasis
28
Cholangiocarcinoma
26
Triple Negative Breast Neoplasms
25
Pancreatic Neoplasms
25
Ovarian Neoplasms
24
Head and Neck Neoplasms
19
Liver Neoplasms
18
Carcinoma, Renal Cell
17
Recurrence
16
Melanoma
15
Stomach Neoplasms
13
Prostatic Neoplasms
13
Carcinoma
13
Endometrial Neoplasms
12
Uterine Cervical Neoplasms
11
Esophageal Neoplasms
11
Carcinoma, Transitional Cell
11
Lymphoma, Large B-Cell, Diffuse
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Lutetium
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
durvalumab
×
Clear all
NCT05063565
2026-04-29
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled
NCT06463665
2025-09-26
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled